Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research


We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program.

DEA 281

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators


Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.

DEA 199

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research


Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. Here, DEA can act with little expenditure of resources.”.

DEA 114

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada.

Justice Department Urged To Take “Immediate Action” On Marijuana Grow Applications


Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue.

Legislation To Produce And Research Cannabis Introduced


A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. The act ends the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes, by requiring the licensing of additional manufacturers.

Approval of Epidiolex Validates What Many CBD Users Already Knew


Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. Further, in support of GW’s application, the company conducted nonclinical and clinical studies to assess the abuse potential of CBD.

Reminder: These are the draft cannabis bills the House Energy and Commerce Subcommittee on Health Will Look At This Week

Cannabis Law Report

It would also open up medical marijuana access to veterans, allowing Department of Veterans Affairs health providers to “provide information to veterans about federally-approved cannabis clinical trials, and to participate in such trials if registered under the CSA.”.

Cannabis and International Trade: Never the Twain Shall Meet?

Canna Law Blog

Drug Enforcement Administration (DEA) granted permission for a Canadian marijuana company (Tilray) to export medicinal cannabis to University of California San Diego for clinical trial.

DEA 106

Article: Thai Govt To Monetize Medical Cannabis

Cannabis Law Report

It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July.

Guest Post: Is CBD Legal? Federal & State Laws [2019]

Cannabis Law Report

Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Felipe Rivera. contact@emperorcbd.com.



A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Backed by grants from the National Institute of Health (and with a license from the DEA ), McAllister discovered that cannabidiol ( CBD ), a nonpsychoactive component of the marijuana plant, is a potent inhibitor of breast cancer cell proliferation, metastasis, and tumor growth.

US Hemp Roundtable: Statement On The Status of Hemp Derived CBD Under Federal Law

Cannabis Law Report

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. Authors.

Buzzes & Bummers: 2018 Was a Wild Ride in the World of Cannabis


It took a whole lot of rolling (joints) and scrolling (old news feeds) to complete a thorough review of the most important, inspiring and infuriating stories about cannabis from the past year—and no doubt I still missed a few along the way.

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.